Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Virologie (Montrouge, France)|November 10, 2021
[Foamy virus, an original retroviral model]J Lehmann-Che, N Renault, M-L Giron, et al.
Annales Pharmaceutiques Francaises|April 27, 2002
[Research activities of interns in pharmacy]D Che, J Lehmann-Che, M Camus, et al.
The Journal of Biological Chemistry|December 29, 2000
Two mild cystic fibrosis-associated mutations result in severe cystic fibrosis when combined in cis and reveal a residue important for cystic fibrosis transmembrane conductance regulator processing and functionJ Clain, J Fritsch, J Lehmann-Che, et al.
British Journal of Cancer|April 25, 2013
Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumabM Cizkova, M-E Dujaric, J Lehmann-Che, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 5, 2018
Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancerDavid Groheux, L Biard, J Lehmann-Che, et al.
Breast Cancer Research and Treatment|September 5, 2016
BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapyA S Hamy, I Bieche, J Lehmann-Che, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 5, 2023
Prognosis and molecular characteristics of IBD-associated colorectal cancer: Experience from a French tertiary-care centerN Hammoudi, J Lehmann-Che, J Lambert, et al.
British Journal of Cancer|February 27, 2014
Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimenS Giacchetti, R Porcher, J Lehmann-Che, et al.
Breast (Edinburgh, Scotland)|October 8, 2013
Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: experience of the REMAGUS 02 phase II trialF Valet, P de Cremoux, F Spyratos, et al.
British Journal of Cancer|May 5, 2011
Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approachesJ Lehmann-Che, F Amira-Bouhidel, E Turpin, et al.
Pageof 2